Business briefs: Layoffs at Roche and Merck, plus pipeline news

Share this article:

Both Roche Diagnostics and Merck are downsizing their manufacturing operations. The Indianapolis Star reported that Roche Diagnostics will cut an unspecified number of jobs at two central Indiana locations in response to “rapidly evolving” change in the US diabetes care market. Retuers reported in May that Roche Holding AG was considering a sale of its blood glucose meter business, which reportedly has a strong presence at the Indiana plants. Meanwhile, a Merck spokesperson confirmed that it's laying off 100 people at its Kenilworth, NJ, plant as it moves manufacturing operations to Tennessee. It's part of a plan, announced earlier this year, to consolidate manufacturing worldwide. The Kenilworth facility "will remain part of Merck and will evolve and grow into an important research facility for us," the spokesperson told MM&M.

Novartis said today that its Phase III study of Afinitor for locally advanced or metastatic hepatocellular carcinoma—the most common form of liver cancer—failed to meet is primary endpoint of overall survival. Subsequently, the drug maker will not pursue regulatory filings for this indication.

An FDA advisory committee gave Bayer's experimental lung drug Riociguat a thumbs-up this past Tuesday to treat two types of pulmonary hypertension. The voting was unanimous at 11-0. If approved, the drug would be dubbed Adempas. An estimate of six analysts polled by Thompson Reuters has the drug forecast to generate sales of $610 million.

New Vivus CEO Tony Zook confirmed in the company's 2Q earnings call that the company now has no plans for launching a DTC campaign for Qsymia. Zook said during the call: “Where we stand today with retail channel and our commercial access, I just don't think [a DTC campaign] would be a good use of our overall spend.” Qsymia is currently being sold at 10,000 certified retail pharmacies, said Vivus commercial head Michael Miller.

Isis Pharmaceuticals nixed development of ISIS-CRPX for rheumatoid arthritis (RA) after a mid-stage trial failed to show significant improvements of disease symptoms. The drug maker said subjects showed some improvements in RA symptoms but none that were statistically significant.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.